Department of Pathology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Front Public Health. 2022 Jul 25;10:926058. doi: 10.3389/fpubh.2022.926058. eCollection 2022.
While timely assessment of long-term survival for patients with cervical cancer is essential for the evaluation of early detection and screening programs for cervical cancer, those data are extremely scarce in China. We aimed to timely and accurately assess long-term survival for patients with cervical cancer in eastern China, using cancer registry data from Taizhou, eastern China.
Patients diagnosed with cervical cancer during 2004-2018 from four cancer registries with high-quality data from Taizhou, eastern China were included. A period analysis was used to calculate the 5-year relative survival (RS) overall and on stratification by sex, age at diagnosis, and region. Additionally, the projected 5-year relative survival (RS) of patients with cervical cancer during 2019-2023 was evaluated, using a model-based period analysis.
Overall 5-year RS for patients with cervical cancer during 2014-2018 reached 90.9%. When stratified by age at diagnosis, we found a clear age gradient for 5-year RS, declining from 95.6% for age <45 years to 68.7% for age >74 years, while urban areas had higher 5-year RS compared to rural areas (92.9 vs. 88.6%). We found a clear increasing trend of 5-year RS during 2004-2018 overall and on stratification by region and age at diagnosis. The projected overall 5-year RS is expected to reach 94.2% for the period 2019-2023.
We found that, for the first time in China, using period analysis, the most up-to-date (during 2014-2018) 5-year RS for patients with cervical cancer reached 90.9%. Our data have important implications for the timely evaluation of early detection and screening programs for patients with cervical cancer in eastern China.
及时评估宫颈癌患者的长期生存率对于评估宫颈癌的早期发现和筛查计划至关重要，但中国此类数据极其匮乏。本研究旨在利用中国东部泰州的癌症登记数据，及时、准确地评估中国东部宫颈癌患者的长期生存率。
本研究纳入了来自中国东部泰州四个高质量癌症登记处，于 2004 年至 2018 年期间诊断为宫颈癌的患者。采用时期分析计算了总体和按性别、诊断时年龄和地区分层的 5 年相对生存率（RS）。此外，还使用基于模型的时期分析评估了 2019 年至 2023 年期间宫颈癌患者的预计 5 年相对生存率（RS）。
2014-2018 年期间，宫颈癌患者的总体 5 年 RS 达到 90.9%。按诊断时年龄分层，我们发现 5 年 RS 存在明显的年龄梯度，从<45 岁年龄组的 95.6%下降到>74 岁年龄组的 68.7%，而城市地区的 5 年 RS 高于农村地区（92.9%比 88.6%）。我们发现，总体而言，2004 年至 2018 年期间，以及按地区和诊断时年龄分层，5 年 RS 呈明显上升趋势。预计 2019-2023 年期间，总体 5 年 RS 预计将达到 94.2%。
我们首次利用时期分析发现，在中国（截至 2014-2018 年），最新（2014-2018 年）宫颈癌患者的 5 年 RS 达到 90.9%。我们的数据对及时评估中国东部宫颈癌患者的早期发现和筛查计划具有重要意义。
